Status:
COMPLETED
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University
Conditions:
Tumor Positron-Emission Tomography
Eligibility:
All Genders
18-80 years
Phase:
PHASE1
PHASE2
Brief Summary
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasophary...
Detailed Description
Patients with newly diagnosed or previously treated NPC will be recruited in this study. Each patient received an intravenous injection of 68Ga-DOTATATE (2-4mCi) on the first day and 68Ga-FAPI (2-4mC...
Eligibility Criteria
Inclusion
- Patients of either gender, aged ≥ 18 years.
- Patients with newly diagnosed or previously treated NPC
- A diagnostic magnetic resonance imaging (MRI) of the tumor region within the previous 1 weeks prior to dosing day is available.
- signed written consent.
Exclusion
- pregnancy
- breastfeeding
- the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
Key Trial Info
Start Date :
November 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2023
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT05990998
Start Date
November 20 2022
End Date
September 1 2023
Last Update
February 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005